SLC5A2 and type 2 diabetes mellitus: Empagliflozin (EMPA) is a sodium‐glucose cotransporter 2 (SGLT2) inhibitor used as an oral medication for treating and managing type 2 diabetes mellitus (T2DM) by improving glycaemic control, reducing glucotoxicity, enhancing glucose metabolism, and decreasing insulin resistance.